STI-6643 had no significant on-target/off-tumor toxicities and a good PK profile without needing low-dose priming sometimes required for competitor antibodies to mitigate the anemia and reduce CD47 expression on circulating erythrocytes (19). The gene discussed is CD47; the disease is neoplasm.